Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Prediction of Creatinine Clearance from Serum Creatinine

1976 • 15,066 citations

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

2003 • 2,871 citations

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 • 2,376 citations

Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission

1999 • 1,607 citations

Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide

1999 • 1,394 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

Chemotherapy with or without Radiation Therapy in Limited Small-Cell Carcinoma of the Lung

1987 • 484 citations

Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer

2004 • 376 citations

Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group

2001 • 289 citations

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

2002 • 245 citations

Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study

1999 • 217 citations

Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.

1987 • 212 citations

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

2004 • 158 citations

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial

2000 • 153 citations

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma

2001 • 149 citations

Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial

2005 • 138 citations

ALIMTA® (pemetrexed disodium) as second-line treatment ofnon-small-cell lung cancer: a phase II study

2003 • 121 citations

Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

2002 • 120 citations

Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.

1999 • 102 citations

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study

1999 • 95 citations

Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.

1999 • 93 citations

Pemetrexed (Alimta^®): a novel multitargeted antifolate agent

2003 • 92 citations

Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

2005 • 89 citations

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer

2003 • 65 citations

Phase II Study of Pemetrexed in Patients Pretreated with an Anthracycline, a Taxane, and Capecitabine for Advanced Breast Cancer

2005 • 52 citations

Activity of Pemetrexed (ALIMTA®, Multitargeted Antifolate, LY231514) in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline and a Taxane: An Interim Analysis

2001 • 48 citations

O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC)

2003 • 37 citations

Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC)

2005 • 35 citations

Pemetrexed in bladder, head and neck, and cervical cancers

2002 • 22 citations

A phase II trial of pemetrexed in patients with metastatic renal cancer

2003 • 21 citations

Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702

2005 • 19 citations

Pemetrexed in bladder, head and neck, and cervical cancers

2002 • 19 citations

Comparable activity with oral topotecan/cisplatin (TC) and IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Final results of a randomized phase III trial (389)

2005 • 14 citations

Pemetrexed (Alimta) in small cell lung cancer

2005 • 13 citations

Paclitaxel/Carboplatin/Etoposide Versus Paclitaxel/Topotecan for Extensive-Stage Small Cell Lung Cancer: A Minnie Pearl Cancer Research Network Randomized, Prospective Phase II Trial

2005 • 12 citations

Pemetrexed in pancreatic cancer

2002 • 8 citations

Pemetrexed in pancreatic cancer

2002 • 8 citations